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Objective: The aim of this study was to provide recommendations on initiating and maintaining
long-acting injectable antipsychotics (LAIs) in individuals with schizophrenia/schizoaffective
or bipolar disorder.
Methods: A 50-question survey comprising 916 response options was completed by 34 expert
researchers and high prescribers with extensive LAI experience, rating relative appropriateness/importance on a 9-point scale. Consensus was determined using chi-square test of score
distributions. Results of 21 questions comprising 339 response options regarding LAI initiation, maintenance treatment, adequate trial definition, identifying treatment nonresponse, and
switching are reported.
Results: Experts agreed that the most important LAI selection factor was patient response/
tolerability to previous antipsychotics. An adequate therapeutic LAI trial was defined as the
time to steady state ± 1–2 injection cycles. Experts suggested that oral efficacy and tolerability
should be established before switching to an LAI, without consensus on the required time,
and that the time for oral supplementation and next injection interval should be determined by
the time to attainment of therapeutic LAI levels. Most experts agreed that $1 adequate LAI
trial is needed to identify the lack of efficacy. There was little agreement about strategies for
switching between LAIs.
Conclusion: Expert guidance may aid clinicians in their decisions regarding initiating/
maintaining LAIs in individuals with schizophrenia/schizoaffective or bipolar disorder.
Keywords: expert consensus, schizophrenia, schizoaffective disorder, bipolar disorder, longacting injectable antipsychotics

Introduction
In individuals with schizophrenia or bipolar disorder, long-acting injectable antipsychotics (LAIs) have been shown to be beneficial in preventing relapse.1 An important
issue in these individuals is poor medication adherence, which can negatively affect
clinical outcomes. In bipolar disorder, poor adherence is associated with mood relapses
(particularly depressive episodes), an increased risk of hospitalization and emergency
room visits, and increased employee costs due to greater absenteeism, short-term
disability, and workers’ compensation.2 Similar consequences are associated with
schizophrenia and schizoaffective disorder because of relapse resulting from poor
adherence.3 Some of the factors that may contribute to reduced adherence include side
effects (perceived or actual), poor efficacy, lack of social support, cognitive deficits,
complexity of treatment regimens, religious or cultural beliefs, limited insight into need
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for treatment, substance use disorder, treatment access or
cost issues, inadequate or lack of health insurance, and an
unstable living environment.4,5
Although currently underutilized in comparison with oral
antipsychotics, LAIs can be an important treatment option
for addressing the high rates of poor adherence to medication
in individuals with serious mental illness.6–11 LAIs possess
several important features that may help improve adherence
in individuals with schizophrenia/schizoaffective disorder or
bipolar disorder, including elimination of the need for daily
administration, enabling health care providers (HCPs) to be
alerted and intervene if the LAI is not taken, and a guarantee
of administration and transparency of adherence. When an
individual is being administered an LAI and relapse does
occur, the HCP knows that relapse is due to a reason other
than nonadherence.9 Importantly, LAIs may reduce the risk of
relapse and hospitalization, which can affect health outcomes,
quality of life, and health care costs.12 Although meta-analyses of early randomized controlled trial data failed to show
consistent superiority of LAIs over oral antipsychotics with
regard to relapse prevention, hospitalization, or secondary
outcomes,13 these studies often did not adequately represent
real-world practice.12,14 Subsequent analyses of LAI mirror
image studies12 and cohort studies,15 which may better represent real-world individuals and more typical practice settings,
suggested that LAIs may be superior to oral antipsychotics in
preventing hospitalization in patients with schizophrenia.12
Although LAIs appear to be a potentially useful element of the treatment armamentarium for schizophrenia/
schizoaffective or bipolar disorder based on these data, there
is a lack of published evidence and treatment guidelines on
optimal strategies for the initiation and maintenance of treatment with LAIs, which would at least partly explain why
LAIs remain underutilized.2,16–18 Most guidelines in the US
support atypical LAIs as an effective option for managing
nonadherence; however, recommendations for LAI use are
not standardized. Expert consensus guidelines supported by
the French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) suggest that psychiatrists
should inform patients about LAIs and offer an LAI as a
first-line treatment to most individuals who require long-term
antipsychotic treatment.18 In contrast, the American Psychiatric Association guidelines recommend these agents for use
only in the case of recurrent relapses due to nonadherence or
in individuals who would prefer an LAI.17 Guidelines from
the Canadian Network for Mood and Anxiety Treatments
recommend the LAI, risperidone, as first-line maintenance
monotherapy in addition to other antipsychotics in bipolar
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disorder as well as an adjunctive therapy with lithium or
divalproex.2 A more recent systemic review and expert
consensus for LAIs in bipolar disorder recommended using
an LAI in individuals with schizophrenia, bipolar I disorder,
rapid cycling bipolar disorder, and bipolar-type schizoaffective disorder.16 This report also recommends use of LAIs in
individuals with bipolar disorder at risk for or demonstrating
poor adherence and multiple episodes, infrequent but serious
episodes, residual symptoms while taking multiple oral
agents, or a preference for an LAI over oral medications.16
Given the lack of supporting clinical trial data, inadequate
evidence base, and overall low use of LAIs despite indications of compelling advantages with respect to adherence
and other outcomes, additional guidance on the use of LAIs
is needed to address gaps in the literature and inform their
appropriate use in individuals with serious mental illness.

Aims of the study
To address gaps in knowledge regarding appropriate LAI
use, an expert consensus survey of US experts was conducted
to obtain recommendations on the clinical use of LAIs in
individuals with schizophrenia/schizoaffective and bipolar
disorders. A companion paper has been developed providing
expert guidance on identifying appropriate individuals for
LAI prescribing, potential barriers to LAI use, and potential
facilitators that would help HCPs decide to administer an
LAI.48 The purpose of this analysis of the expert consensus
survey was to provide guidance on initiation and maintenance
treatment with LAIs in individuals with schizophrenia/
schizoaffective and bipolar disorders.

Materials and methods
This expert consensus survey assessed the relative appropriateness of LAI treatment for several patient characteristics and
clinical scenarios as well as optimal prescribing practices for
initiation and continuation/maintenance treatment with LAIs.
For the purpose of this survey, LAIs were considered as one
group, and a distinction between typical and atypical antipsychotics was not made. The survey was administered online via
SurveyMonkey® (SurveyMonkey Inc., San Mateo, CA, USA)
between April and November 2016 and contained 50 questions
(a total of 916 response options). Respondents’ opinions and
practices regarding LAI prescribing for individuals with schizophrenia/schizoaffective and bipolar disorders were elicited from
the experts surveyed. In line with the patient assessment and
clinical decision-making process, the survey consisted of three
overarching and sequential sections: 1) identifying patients, 2)
initiation of therapy, and 3) maintenance treatment.
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A 9-point scale adapted from the RAND method19 was
used by survey respondents to rate predefined options with
some questions including a write-in or comment option.
The rating scale ranged from 1 to 9: 1 represented the least
appropriate or worst option and 9 represented the most
appropriate or best option. The exact wording of the worst
to best terminology was slightly modified depending on a
question’s context (ie, 1 indicated extremely inappropriate,
strongly disagree, or not important at all; 9 indicated
extremely appropriate, strongly agree, or extremely important). Options rated as first line were considered as very or
usually appropriate, second line as somewhat appropriate,
and third line as inappropriate. In completing the survey,
respondents were asked to draw on their personal clinical
experience in treating individuals with schizophrenia/
schizoaffective and bipolar disorders as well as their
knowledge of research and/or published literature. The
survey was distributed to 42 experts in the US who were
either researchers in mood and psychotic disorders with
expertise in LAI trials or clinicians with extensive expertise
in the use of multiple LAI formulations. The time required
to complete the survey was approximately 2.5–3.0 hours.
Each academic expert met two or more of the following
inclusion criteria: has published in the area of adherence
or LAI use as it relates to individuals with schizophrenia/
schizoaffective and bipolar disorders; is a principal investigator or coprincipal investigator for studies involving LAIs
for the treatment of schizophrenia or bipolar disorder; has
an advanced degree in psychology, medicine, or an associated field; and is responsible for the selection of treatment
options for patients with schizophrenia/schizoaffective and
bipolar disorders. Each clinician with extensive expertise
fulfilled the following criteria (based on prescribing data):
routinely prescribes LAIs in their practice; prescribes at
least two different LAIs in their practice; has an advanced
degree in psychology, medicine, or associated field; and is
responsible for the selection of treatment options for their
patients with schizophrenia/schizoaffective and bipolar
disorders. Respondents received an honorarium for their
participation in the survey and were blinded to the study
sponsor. Respondents were informed of the purpose of the
survey and invited to continue by clicking a web button,
which was deemed as confirming agreement. This study only
involved the use of survey procedures and did not involve
children, and the responses were aggregated and anonymized such that none of the responses could be linked to
any specific respondent; this study is exempt from approval
by an institutional review board.

Neuropsychiatric Disease and Treatment 2018:14
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Statistical analyses
The presence or absence of consensus on each question was
defined as a distribution unlikely to occur by chance using the
chi-square test (P,0.05) across three ranges of appropriateness on the rating scale (ie, 1–3, 4–6, and 7–9). Consistent
with previous expert consensus survey methodology,20 the
mean rating with 95% CI was calculated for each option in a
given question. Results were summarized graphically with a
horizontal box representing the 95% CI for each consecutive
option in a given question. Options receiving a rating of 9
by $50% of respondents were marked by an asterisk, and
shading was used to indicate consensus. CIs of mean ratings
were used to designate first-, second-, or third-line ratings
(ie, items were first line if the bottom of the CI boundary
was .6.5, second line if the bottom of the CI fell between
3.5 and 6.5, and third line [not appropriate] if the bottom of
the CI was ,3.5). Tests of significance were not performed
for most items; however, wider gaps between CIs generally
indicated smaller P-values.
Expert consensus related to initiation and maintenance
treatment with LAIs in individuals with schizophrenia/
schizoaffective and bipolar disorders is summarized in
this study.

Results
Of 175 experts who were invited to take the survey, 42
(24%) agreed to participate, and 81% (34 out of 42) of
those who received the survey completed it. A list of survey
respondents and their demographics and experience have
been provided in a companion paper.48 The majority of the
expert panel was composed of psychiatrists (n=24), of whom
seven were clinicians with extensive expertise in the use
of multiple LAIs (high prescribers). Overall, experts had
a relatively high level of clinical experience, with .50%
reporting they spent either half, a majority, or all of their
time in clinical practice. The expert panel also reported
spending a mean of 30% of their time either treating or
supervising the treatment of individuals with schizophrenia/schizoaffective disorder and 25% of their time either
treating or supervising the treatment of individuals with
bipolar disorder. Within the clinical practices of the selected
experts, 33% of patients with schizophrenia/schizoaffective
disorder and 11% with bipolar disorder were being treated
with LAIs. In response to the first survey question, which
asked how confident these experts were in assessing their
patients’ adherence to oral medication, most of the experts
indicated that they were only somewhat confident (45%) or
not very confident (33%).
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Optimal practices and procedures before
initiating an LAI and partnering with
patients

educating patients and families, normalizing the use of LAIs,
and engaging patients in a treatment plan that includes LAIs.

Experts rated the appropriateness of initiating treatment with
an LAI in the context of various predetermined treatment
settings. The experts considered it appropriate to initiate an
LAI in a wide range of treatment settings and clinical situations (Figure 1A). First-line consensus was achieved for
outpatient, community mental health clinic, correctional or
forensic, and inpatient treatment settings as well as the following situations: availability of support/ancillary staff to discuss
LAIs with patient and/or administer LAI, family supportive
of LAI treatment, and patient covered by Medicare and/or
Medicaid. High second-line consensus was achieved for courtordered inpatient or outpatient treatment, patients covered by
private health insurance, and private practice settings.

LAIs possess a number of potential advantages that may
help patients accept treatment. Experts rated which LAIassociated benefits would motivate patients to use LAIs, and
the following benefits were considered first line/extremely
important (rating of 9 by $50% of experts; Figure 1C):
a better chance of preserving functioning and achieving
long-term goals if on continuous medication, reduced risk
of relapse, and easier to be adherent (only need to remember
to go for injections).

Appropriate treatment settings for initiation

Important steps in initiating treatment
When rating the importance of various steps in initiating an
LAI, .65% of experts gave a rating of 9 (first line; extremely
important) to discussing the risks and benefits of LAI treatment with the patient and family/care partners as well as for
obtaining the patient’s agreement to LAI treatment. Additional
steps achieving consensus as being extremely important are
shown in Figure 1B. Overall, the experts placed importance on

A

Partnering/discussing LAIs with patients

Factors to consider in selecting an LAI
Experts rated patient-, system-, and medication-related
factors that might be considered in selecting a specific
LAI (Table 1). The patient’s previous response to specific
antipsychotics and history of side effects were rated as the
most important patient-related factors to consider (first line;
extremely important). Out-of-pocket patient expense and formulary/insurance restrictions were rated as the most important system-related factors (both rated as first line/usually
important), whereas the most important medication-related
factors were the clinician’s belief that a specific LAI would
provide the best tolerability and efficacy profiles, availability
of different formulations with varying dosing intervals, and

Question 9. Appropriate treatment settings for initiation. Assume that you are considering initiating
treatment with an LAI in a patient with schizophrenia, schizoaffective disorder, or bipolar disorder. Please
rate the appropriateness of initiating treatment with an LAI in the context of each of the following treatment settings
Third line

95% CIs

Second line

First line

N

Mean (SD)

Availability of support/ancillary staff
(eg, nurse, injection clinic) to discuss
LAI with patient and/or administer LAI

34 7.9 (1.7)

Family supportive of LAI treatment

34 7.9 (1.2)

Outpatient treatment setting

33 7.5 (1.8)

Community mental health clinic

34 7.4 (2.0)

Penal or forensic setting

33 7.3 (1.9)

Inpatient treatment setting

34 7.3 (2.0)

Patient covered by Medicare and/or Medicaid

34 7.3 (2.0)

Court-ordered outpatient treatment

34 7.1 (2.1)

Court-ordered inpatient treatment

33 6.8 (2.5)

Patient covered by private health insurance

34 6.7 (2.5)

Private practice setting

33 6.5 (2.3)

Availability of peer specialist support (peer
specialists and educators are other patients who
have been trained to educate/deliver care)

34 6.2 (2.6)

1

2

3

4

5

6

7

8

9

Figure 1 (Continued)
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B

Question 10. Important steps in initiating treatment. Please rate the importance of each of the following
steps in initiating treatment with an LAI in a patient with schizophrenia, schizoaffective disorder, or bipolar disorder
Third line

95% CIs

Second line

First line

Mean (SD)

Discuss risks and benefits of LAI treatment
with patient

*

34 8.7 (0.7)

Discuss risks and benefits of LAI treatment with
family/care partners if involved in treatment

*

34 8.6 (0.7)

Obtain patient agreement to treatment
with an LAI

*

34 8.4 (1.2)

Document discussion with patient (and care
partner if involved) in medical record

*

34 8.4 (0.9)

Discuss use of LAI as part of the care plan with
other members of the treatment team (eg,
case manager, psychotherapist)

34 8.1 (1.2)

Provide patient (and care partner if involved)
with educational materials concerning possible
side effects of LAls (written or other format)

34 7.8 (1.5)

Provide patient (and care partner if involved)
with educational materials concerning possible
benefits of LAls (written or other format)

34 7.7 (1.5)

Provide patient (and care partner if involved)
with educational materials concerning the
impact of staying on medication/adherence on
long-term outcomes (written or other format)

34 7.7 (1.7)

*

Provide information/referral concerning patient
assistance programs or other available
financial supports

34 7.4 (1.7)

Obtain written informed consent from patient to
LAI treatment

33 6.4 (2.5)
1

C

N

2

3

4

5

6

7

8

9

Question 11. Discussing LAls with patients. Assume you are planning to discuss initiating treatment with
an LAI with one of your patients who has schizophrenia, schizoaffective disorder, or bipolar disorder. How important
do you believe each of the following potential benefits of LAIs would be in motivating patients to want to use an LAI?
Third line

95% CIs

Second line

First line

Better chance of preserving functioning and
achieving long-term goals if on continuous
medication
Reduced risk of relapse
Easier to be adherent (only need to remember
to go for injections)

N

Mean (SD)

*

34 8.2 (1.2)

*

34 8.2 (1.4)
34 8.0 (1.3)

*
*

Less burden to receive injections than
remembering to take daily medication

34 7.7 (1.1)

Reduced symptoms because of continuous
medication coverage

34 7.5 (1.7)

Family/care partners will feel more comfortable

34 7.3 (1.3)

Helps to avoid long-term changes in the brain or
more treatment-resistant illness associated with
poorly controlled disease

34 7.0 (2.0)
*

Fallback mechanism if adherence starts to drop
off (staff will know if injections are missed)

34 6.8 (1.7)

More time to focus on non-medication-related
issues rather than adherence issues in clinical
sessions

34 6.7 (1.9)

Less fluctuation in blood levels which may
produce a more consistent response and may
allow use of a lower dose

34 6.6 (2.1)

Less stigmatizing (avoid stigma associated with
having to take daily psychiatric medication)

34 6.5 (2.0)
1

2

3

4

5

6

7

8

9

Figure 1 Procedures before initiating an LAI and partnering with patients.
Notes: (A) Appropriate treatment setting for initiating treatment with an LAI (rating scale: 1, not appropriate at all; 9, extremely appropriate), (B) important steps in
initiating treatment with an LAI (rating scale: 1, not important at all; 9, extremely important), and (C) importance of discussing potential benefits of LAIs in motivating patients
to use an LAI (rating scale: 1, not important at all; 9, extremely important). An asterisk in a bar represents an option that received the highest ranking of 9 by $50% of
respondents. Horizontal bars represent CIs. Open bars indicate no consensus; shaded bars indicate consensus (dark shading: first line; medium shading: second line; light
shading: third line). High second line: CI bar crosses the boundary with first line.
Abbreviation: LAI, long-acting injectable antipsychotic.
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Table 1 Factors to consider in selecting an LAI
Patient-related factors

System-related factors

Medication-related factors

Patient’s previous response to LAI,b 8.2 (1.1)

Out-of-pocket expense for the patient,
8.1 (1.0)

Clinician believes the chosen LAI will have the best
tolerability, 7.8 (1.5)

Weight gain, metabolic syndrome, symptoms
of hyperprolactinemia, tardive dyskinesia, or
parkinsonism with previous antipsychotic, 7.9 (1.2)

Formulary or insurance restrictions,
8.0 (1.1)

Clinician believes the selected LAI has the best
chance of being efficacious for the specific patient,
7.7 (1.5)

First-line ratings, mean (SD)
a

Symptoms of hyperprolactinemia with previous
antipsychotic therapy, 7.7 (1.3)

Availability of longer-acting formulation (injections
can be given less frequently), 7.7 (1.5)

Patient’s previous response to oral antipsychotic,
7.7 (1.3)

LAI that allows for longer interval when a dose is
missed before oral augmentation required, 7.5 (1.0)

Tardive dyskinesia with previous antipsychotic
therapy, 7.4 (1.9)

Availability of different formulations with varying
dosing intervals, 7.1 (1.5)

Parkinsonism with previous antipsychotic therapy,
7.2 (1.4)

LAI that can be given via deltoid as well as gluteal
injection, 7.0 (1.3)

High second-line ratings,a mean (SD)
Akathisia, sedation, or sexual dysfunction with
previous antipsychotic, 7.1 (1.8)

Clinician’s personal experience using a
specific LAI, 6.9 (2.2)

Availability of prefilled syringes for LAI
administration, 6.8 (1.5)

Persistent positive symptoms in a patient with
SCZ, 6.9 (1.9)

No availability of appropriately monitored
refrigeration facilities, 6.6 (2.1)

Availability of multiple dosing strengths in prefilled
syringes, 6.7 (1.6)

Sedation with previous antipsychotic therapy,
6.7 (1.8)

Properties of the specific antipsychotic molecule,
5.9 (2.0)

Sexual dysfunction with previous antipsychotic
therapy, 6.5 (2.2)

Package insert recommends LAI dosing that takes
into account hepatic metabolism status, 5.8 (1.7)

Persistent manic symptoms in a patient with
bipolar disorder, 6.5 (1.8)
Medical comorbidity involving cardiovascular
disease, 6.3 (1.9)
Medical comorbidity involving hepatic disease/
dysfunction, 6.2 (2.0)
Borderline or prolonged QTc interval, 6.2 (2.1)
Persistent depressive symptoms in a patient with
SCZ, 6.0 (1.9)
Persistent depressive symptoms in a patient with
bipolar disorder, 5.9 (2.1)
Persistent negative symptoms in a patient with
SCZ, 5.8 (2.2)
Notes: aCIs of mean ratings were used to designate first-line or high second-line ratings (ie, items were first line if the bottom of the CI boundary was .6.5 and high second
line if the bottom of the CI boundary was $3.5 and the top of the CI boundary was .6.5). bOptions that received the highest rating of 9 by $50% of experts.
Abbreviations: LAI, long-acting injectable antipsychotic; SCZ, schizophrenia/schizoaffective disorder.

the ability to administer the LAI via deltoid as well as gluteal
injection (all first line/usually important [defined as a score of
7–8 on the rating scale]). Of note, no consensus was achieved
on how important a history of violence/aggression, presence
of comorbid substance abuse, or a history of suicidality would
be in selecting a specific LAI.

Establishing tolerability and efficacy when initiating
treatment
Assuming a decision has been made to use a specific
LAI, experts rated the most appropriate strategies for
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establishing tolerability and efficacy of the LAI in a patient
who had not previously received this LAI (ie, a unique
molecule). There was little consensus regarding the best
strategy in establishing the tolerability and efficacy of a
molecule (specific drug) before initiating the LAI. Overall,
the experts appeared to prefer shorter intervals (4–14 days)
of oral medication before initiating treatment with an LAI
of the same molecule (second-line rating). However, there
was consensus that they would not recommend continuing the oral medication for .6 weeks before beginning
an LAI with the same molecule (third-line rating; usually

Neuropsychiatric Disease and Treatment 2018:14
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inappropriate [defined as a score of 2–3 on the rating
scale]). The strategy to continue treatment with oral
medication for .8 weeks to ensure both tolerability and
efficacy before initiating an LAI with that same molecule
received the lowest rating and expert consensus as being
usually inappropriate.

Dosing of initial injections
Respondents rated the appropriateness of prescribing a lower
initial dose or a higher dose of the LAI than recommended in
the package insert in individuals with schizophrenia, schizoaffective disorder, or bipolar disorder. Generally, there was
little support for initiating an LAI at doses lower or higher
than recommended in the package insert with the following
exceptions: experts gave high second-line ratings to starting
with a lower initial dose of the LAI in older patients as well
as patients who have extrapyramidal side effects to minimize
side effect burden. The experts gave high second-line ratings
to initiating treatment with a higher initial dose of the LAI for
patients who had a history of requiring larger than usual daily
dosages of oral antipsychotics to achieve treatment response
or to prevent relapse. The option to give either a lower or
higher initial dose than recommended in the package insert
to all individuals with schizophrenia/schizoaffective disorder
or bipolar disorder received the lowest rating and achieved
consensus as being usually inappropriate.

Timing of the second injection
Experts rated the most important factors that would determine
the timing of the second LAI injection. Experts achieved
consensus that the most important factors were the package
insert recommendations and the patient showing an increase
in symptoms before the end of the dosing interval (first-line
recommendation; both were rated as usually important).
High second-line consensus was also attained for the length
of time to achieve therapeutic levels (usually appropriate),
pharmacologic/molecular properties of the antipsychotic
agent (usually appropriate), presence of side effects believed
to be due to the LAI (sometimes appropriate [defined as a
score of 4–6 on the rating scale]), and severity of the patient’s
psychiatric symptoms (sometimes appropriate).

Managing oral antipsychotics during and after
initiation of an LAI
When queried regarding starting dose, the use of loading
doses, the procedure for switching from oral antipsychotic
to LAI (eg, duration of overlap), and interval between injections, the experts overwhelmingly agreed that they generally

Neuropsychiatric Disease and Treatment 2018:14
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follow package insert recommendations if provided. When
asked to rate appropriateness of several schedules for tapering
and discontinuing oral supplementation (if recommended in
the package insert [PI]) after the period of time recommended
in the PI, the experts gave high second-line ratings to discontinuing oral supplementation exactly as recommended in
the package insert. They would also consider tapering off the
oral antipsychotic over an additional 1–3 weeks (second-line
rating); however, they would not recommend continuing oral
antipsychotic supplementation beyond 3 weeks (ie, maintain
regular dosing for only a short time frame and not longer
term). The strategy to taper or discontinue oral antipsychotic
medication after an additional period of .3 months after the
period of oral supplementation recommended in the package insert received the lowest rating and consensus as being
usually inappropriate.

Managing side effects
Experts rated the appropriateness of various medications
to manage distressing side effects in patients who had
recently initiated LAI treatment and in whom the expert
had already considered or tried a decrease in LAI dose.
Experts recommended the following medications as firstline (usually appropriate) treatments for the following side
effects: β-blocker for akathisia/restlessness; an anticholinergic for dystonia or parkinsonism; a non-benzodiazepine
sedative/hypnotic for insomnia; and metformin, statins, and
angiotensin-converting enzyme inhibitors for the metabolic
syndrome component abnormalities of elevated glucose, lipid
abnormalities, and high blood pressure, respectively.
In addition, high second-line recommendations (all were
rated as sometimes appropriate) achieved consensus for the
use of a sedative/hypnotic or anticonvulsive agent for agitation, oral partial D2 agonist antipsychotic (if not on partial D2
agonist LAI) for prolactin-related side effects, and a drug
targeting erectile dysfunction for sexual dysfunction.

Optimal practices for continuation and
maintenance treatment with LAIs
Optimizing maintenance treatment

For maintenance treatment, experts rated the ideal time
interval between LAI injections, independent of the specific
characteristics of the drug/delivery system. Although no
first-line recommendations were achieved, high second-line
ratings (usually appropriate) were given for intervals ranging
from 4 to 12 weeks, with no consensus on longer intervals
ranging from 6 to 12 months and little support for injections
given at shorter intervals (ie, every 2 weeks; Figure 2A).
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Supporting adherence to appointments for LAI
injections

Consensus was not achieved among the experts on the utility
of technology-focused alerts (eg, text messages and emails)
in reminding patients to keep an appointment; there was only
minimal support for using mailed reminders.

Because maintaining long-term adherence is a difficult goal
for many patients,21 experts rated strategies to optimize
adherence to appointments for LAI administration. Four
strategies achieved consensus and were recommended by the
experts as first-line (usually appropriate) methods to optimize
adherence to appointments for LAI administration: LAI
administration in the home by mental health care professional,
involvement of family member/partners in care, involvement
of peer specialist/counselor in care, and telephone reminders about appointments for LAI administration (Figure 2B).

A

Assessing response: most important clinical
symptoms
Experts rated the clinical symptoms they considered important to target in evaluating therapeutic response to an LAI.
In individuals with schizophrenia/schizoaffective disorder,
experts gave first-line recommendations to monitoring positive symptoms (eg, psychosis, delusions, and hallucinations),

Question 32. Optimal interval between injections. In clinical practice, LAIs are administered using different
dosing intervals depending on a variety of factors including injection dose and drug delivery system. If you
could pick an “Ideal” dosing interval independent of specific characteristics of a given drug/delivery system
that is based upon what you believe to be ideal for patients and clinicians, what would you consider the
ideal optimal frequency of administration of a long-acting antipsychotic?

95% CIs

Third line

Second line

First line

N Mean (SD)

Every 8 weeks

33

7.0

(1.9)

Every 4 weeks

33

7.0

(2.0)

Every 12 weeks

32

6.9

(2.1)

Every 6 weeks

31

6.6

(1.6)

Every 6 months

33

5.7

(2.2)

Every 12 months

32

4.7

(2.7)

Every 9 months

32

4.6

(2.2)

33

4.2

(2.1)

Every 2 weeks
1

B

2

3

4

5

6

7

8

9

Question 33. Supporting adherence to appointments for LAI injections. Long-term adherence to LAIs is
typically problematic, with patients showing an initial improvement in adherence that is not maintained after
6–12 months. We are interested in the strategies that you have found most effective in getting your patients
to come in for regular injections. Please rate the effectiveness of the following stategies/supports during
maintenance treatment with an LAI to optimize the patient’s adherence to appointments for LAI administration
Third line

95% CIs

Second line

First line

N Mean (SD)

LAI administration in the home by mental
health professional

33

8.3

(1.0)

Involvement of family member/care partner to
remind patient

33

8.2

(0.8)

Involvement of peer specialist/counselor to
remind patient

33

7.7

(1.0)

Telephone reminders about appointments
for LAI administration

33

7.3

(1.4)

Text messages about appointments for LAI
administration

33

6.1

(2.1)

Emails about appointments for LAI
administration

33

4.9

(2.3)

Mailed reminders about appointments for LAI
administration

33

4.3

(2.1)

1

2

3

4

5

6

7

8

9

Figure 2 Optimizing maintenance treatment and supporting LAI adherence.
Notes: (A) Optimal interval between injections (rating scale: 1, extremely inappropriate; 9, extremely appropriate) and (B) effectiveness of strategies during maintenance
treatment with an LAI to optimize the patient’s adherence to appointments for LAI administration (rating scale: 1, likely to be ineffective; 9, likely to be effective). Horizontal
bars represent CIs. Open bars indicate no consensus; shaded bars indicate consensus (dark shading: first line; medium shading: second line; light shading: third line). High
second line: CI bar crosses the boundary with first line.
Abbreviation: LAI, long-acting injectable antipsychotic.
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which received the highest rating of 9 from 79% of the
experts (extremely important), and functional status (eg,
social and occupational; considered to be usually important).
In individuals with bipolar disorder, experts considered
psychotic symptoms, manic/hypomanic symptoms, and
mixed symptoms, all of which received the highest rating
of 9 from 79% of the experts (extremely important), as most
important in evaluating therapeutic response to an LAI.
Functional status and rate of mood cycling were rated as
usually important.

Defining an adequate trial of an LAI
Because the definition of an adequate LAI trial is not established, experts rated how important they considered the time
duration of treatment versus the number of injection cycles
that had been completed to determine whether a patient has
had an adequate trial of an LAI. There were no first-line
ratings. The experts gave high second-line ratings to both
number of cycles once steady-state plasma levels are reached
(rated as 9 by 30% and 7–9 by 67%) and duration of time in
determining whether a patient has had an adequate trial of
an LAI (rated as 9 by 19% and 7–9 by 61%).
Experts were then asked to assume that they had an individual with schizophrenia or schizoaffective disorder who had
been maintained on an LAI at the maximum dosage they were
comfortable administering for this patient and that the patient
had failed to achieve an adequate response. Experts rated the
appropriateness of a number of definitions of an adequate
therapeutic trial of an LAI in this predefined setting. None of
the options received first-line ratings. The experts gave high
second-line ratings to the need for multiple cycles of LAI
injections to ensure an adequate therapeutic trial, with the least
conservative definition being the number of cycles needed to
achieve steady state and a more conservative definition involving one to two cycles beyond steady state or at least 12 weeks of
treatment. The parameter of giving one to two injection cycles
less than needed to reach full steady state received the lowest
rating and consensus as being usually inappropriate.
Similar responses were obtained for determining an
adequate LAI therapeutic trial for an individual with bipolar
disorder. In addition, 66% of the experts indicated that the
patient’s history of mood cycling intervals would affect their
decision concerning the numbers of cycles/periods of time
they would continue LAI treatment before deciding whether
the patient was having an adequate response.

Strategies for inadequate response
If an individual with schizophrenia or schizoaffective disorder was at steady state of the maximum allowed or tolerated
Neuropsychiatric Disease and Treatment 2018:14
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dose of an LAI and had some improvement but either continued to experience persistent residual symptoms or began
to develop breakthrough symptoms, the experts rated the
appropriateness of treatment strategies depending on the type
of symptoms involved (ie, positive/psychotic, negative, or
cognitive symptoms; Table 2). If positive symptoms occurred
(eg, hallucinations, delusions, and aggression), first-line
consensus emerged for switching to a medication approved
for treatment-resistant schizophrenia (rated as usually
appropriate). High second-line consensus was achieved for
switching the patient to an alternative LAI with a different
molecular base or adding the same oral antipsychotic as the
LAI (both rated as sometimes appropriate). Adding estrogen or other hormonal treatments achieved consensus as
being usually inappropriate. If negative symptoms occurred
(eg, lack of motivation), no first-line consensus emerged for
any of the strategies. High second-line consensus emerged for
switching to a medication approved for treatment-resistant
schizophrenia (rated as usually appropriate). Adding an oral
medication to slow down second-pass metabolism of the LAI
received the lowest rating and consensus as being usually
inappropriate. Finally, if cognitive symptoms occurred, no
first-line or high second-line recommendations emerged, and
no consensus on any second-line strategy was achieved by the
experts. Adding electroconvulsive therapy to the treatment
regimen received the lowest rating and consensus as being
usually inappropriate.
Similarly, if an individual with bipolar disorder was at
steady state for the maximum allowed or tolerated dose of
an LAI and had some improvement but either continued
to experience persistent residual symptoms or began to
develop breakthrough symptoms, the experts rated the
appropriateness of treatment strategies depending on the type
of symptoms involved (ie, manic, depressive, or psychotic
symptoms; Table 2). If manic symptoms occurred, firstline consensus emerged for switching to a different mood
stabilizer if the patient is currently being treated with one,
adding lithium, or adding an anticonvulsant mood stabilizer
the patient has not previously received (all rated as usually
appropriate). There was no consensus for any recommended
second-line strategy. The two strategies receiving the lowest
rating and achieving consensus as being usually inappropriate were adding oral medication to slow down second-pass
metabolism of the LAI or adding a different LAI with alternating injection time points. No first-line recommendations
were given in case of occurrence of depressive symptoms;
however, high second-line consensus emerged for the following strategies: adding an antidepressant medication if the
patient is already receiving (or HCP is adding) lithium or an
submit your manuscript | www.dovepress.com
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Table 2 Strategies for an inadequate response to an LAI in patients with schizophrenia/schizoaffective or bipolar disorder
Type of persistent First linea
or breakthrough
symptom

High second linea

Schizophrenia/schizoaffective disorder
Positive symptoms
(eg, hallucinations,
delusions,
aggression)

• Switch to a medication approved for
treatment-resistant schizophrenia, 7.4 (1.9)

Negative symptoms

• Switch to a medication approved for
treatment-resistant schizophrenia, 6.5 (2.4)

• Switch to an alternative LAI with a different molecular base, 6.5 (1.9)
• Add the same oral antipsychotic as the LAI, 6.3 (2.0)
• Decrease time period between injections to a shorter interval,b
6.1 (2.4)

Cognitive symptomsc
Bipolar disorder
Manic symptoms

• Switch to a different mood stabilizer if the
patient is currently being treated with one,
7.4 (1.6)
• Add lithium, 7.4 (1.3)
• Add an anticonvulsant mood stabilizer the
patient has not previously received, 7.4 (1.3)

• Add an anticonvulsant mood stabilizer to which the patient has
previously had at least a partial response, 7.1 (1.8)

Depressive
symptoms

• Add lithium, 6.3 (1.9)
• Add an antidepressant medication if the patient is already receiving
lithium or an anticonvulsant mood stabilizer, 6.1 (2.3)
• Add an anticonvulsant mood stabilizer, 6.0 (2.0)

Psychotic symptoms

• Switch to a medication approved for treatment-resistant schizophrenia,
5.9 (2.6)
• Switch to an alternative LAI with a different molecular base, 5.8 (2.1)
• Add the same oral antipsychotic as the LAI,b 5.7 (2.4)

Notes: aCIs of mean ratings were used to designate first-line or high second-line ratings (ie, items were first line if the bottom of the CI boundary was .6.5 and high secondline if the bottom of the CI boundary was $3.5 and the top of the CI boundary was .6.5). bNo consensus was reached. cNo first-line or high second-line recommendations;
no consensus on any second-line strategy.
Abbreviation: LAI, long-acting injectable antipsychotic.

anticonvulsant mood stabilizer, or adding an anticonvulsant
mood stabilizer (all rated as sometimes appropriate). Adding
an oral medication to slow down second-pass metabolism
of the LAI received the lowest rating and consensus as
being usually inappropriate. The experts did not arrive at
first-line recommendations for any of the treatment strategy
options for persistent or breakthrough psychotic symptoms
occurring on LAI treatment; however, high second-line
consensus emerged for switching to a medication approved
for treatment-resistant schizophrenia or switching to an
alternative LAI with a different molecular base. The lowest
rated strategy was the same as that shown for depressive
symptoms.

Identifying and defining lack of treatment response
Although lack of treatment response is typically defined
as a failure to respond to multiple adequate trials of oral
antipsychotic medications in individuals with schizophrenia/
schizoaffective disorder or bipolar disorder, defining nonresponse to treatment in the context of treatment with an LAI is
not clear. A confounding factor for oral antipsychotic drugs
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is that many individuals are nonadherent or only partially
adherent. Therefore, experts were asked to indicate their
level of agreement with the statement that schizophrenia/
schizoaffective disorder or bipolar disorder should not be
identified as treatment-resistant “without” at least one trial of
an LAI (to ensure that what appears to be refractory illness
is not actually the result of poor adherence with prescribed
treatment). For schizophrenia, 21% of experts strongly agreed
(score of 9 on the rating scale) with the statement, 67% agreed
(rating of 7–9), 21% somewhat agreed (rating of 4–6), and
12% disagreed. Thus, the majority of experts (nearly 90%)
believe that an LAI trial is needed to determine the lack of
therapeutic response to antipsychotic treatment in individuals
with schizophrenia/schizoaffective disorder.
For bipolar disorder, expert agreement was not as high as
for individuals with schizophrenia/schizoaffective disorder;
however, a majority of experts agreed that an LAI trial
was needed to determine the lack of therapeutic treatment
response in bipolar disorder (9% strongly agreed [rating of 9],
52% agreed [rating of 7–9], 33% somewhat agreed [rating
of 4–6], and 15% disagreed).
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Medical monitoring of patients
being treated with an LAI (no major
comorbidities)

Most important medical parameters to monitor
Safety monitoring is important in patients being treated for
severe mental illness;22,23 however, most of the available
guidance for safety monitoring is related to treatment with
antipsychotics in general and not specifically for LAIs. In an
individual being treated with an LAI who has schizophrenia,
schizoaffective disorder, or bipolar disorder and does not have
any major comorbidities (eg, diabetes, hypertension, or active
cardiovascular disease), experts rated body weight/body mass
index (BMI), fasting lipid levels, and standardized assessments
for tardive dyskinesia as the most important medical parameters to monitor (highest rating of 9 by $50% of the experts).
Additional first-line parameters were hemoglobin HbA1c
and fasting glucose level (rated as usually appropriate).

Frequency of medical monitoring
Experts rated the frequency of medical monitoring for the
average patient treated with an LAI, assuming the patient
had no major medical conditions during and after the first
6 months of treatment (Table S1). The medical parameters
receiving the highest ratings by the experts were similar irrespective of the time period assessed (ie, body weight/BMI and
blood pressure), although the experts’ responses indicated
that, for some parameters (eg, liver function and prolactin
abnormalities), the effects would not be expected to appear
immediately after LAI initiation but would rather take weeks
to months to change with sustained LAI treatment.

Switching between LAIs
Because there is currently little guidance available on how to
switch from one LAI to another, the experts rated different
methods of switching LAIs for a patient who had failed to
respond to an LAI after what the experts considered to be a
full therapeutic trial. There was little agreement on appropriate ways to switch between LAIs, with no LAI switching
options rated as extremely appropriate. Regardless of whether
therapeutic levels are reached quickly (eg, within days) or
over a significant period of time (eg, within weeks) with the
prior LAI, if levels are reached quickly with the new LAI,
the experts agreed that the new LAI can be given at the same
time the previous LAI would have been given and at the
same dose recommended in the PI for the new LAI, without
providing a concomitant oral antipsychotic. Of note, free
text comments from the experts stressed the importance of
first establishing oral tolerability of the new antipsychotic.

Neuropsychiatric Disease and Treatment 2018:14
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In contrast, if therapeutic levels are reached quickly with the
prior LAI but over a longer period with the new LAI, experts
agreed that it is sometimes appropriate to supplement therapy
with an oral antipsychotic during the switch.
No first-line or high second-line agreement was achieved,
and no consensus was reached on the best strategy for
switching when significant time is needed to reach therapeutic levels with both the previous and new LAI. Consensus
was reached for the following strategies being usually inappropriate: 1) substituting at the same time the previous LAI
would have been given with either a higher dose of the new
LAI (whether or not an oral antipsychotic is also given) or a
lower dose of the new LAI, and 2) substituting at an earlier
time than the previous LAI would have been given, whether
at a lower or higher dose of the new LAI.
Among the experts who responded (n=31), the most frequent reasons for switching LAIs were suboptimal efficacy
and side effects (38% and 28%, respectively). Finally, of the
30 who responded regarding combining LAIs, 21 (70%) did
not support this practice.

Limitations

• Generalizability of the findings could be reduced by the
fact that a relatively small number of experts invited to
take the survey actually agreed to take the survey.
• Because many clinically relevant areas lacked clinical
trial data, recommendations were based on both trial data
and clinical experience and opinion.

Discussion
Although recent studies indicate that the use of LAIs may
have the potential to prevent relapse compared with oral
antipsychotic use,24–26 and although second-generation LAI
formulations are widely available in the US, it has been
estimated that only 13%–28% of eligible US patients are
actually prescribed LAIs.9 One explanation for why these
agents are potentially underprescribed may be the current
lack of published guidance on how to initiate and maintain
treatment with these agents. The purpose of this expert
consensus survey was to provide recommendations to help
fill in some of the existing knowledge gaps concerning the
appropriate use of LAIs in the treatment of individuals with
schizophrenia/schizoaffective disorder or bipolar disorder.
Results pertaining to initiating and maintaining LAI treatment
are reported in this study (summary is given in Table 3),
whereas additional results pertaining to appropriate patients
and clinical scenarios are reported in a companion paper.48
Overall, expert recommendations in the current survey align
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Table 3 Summary of first-line recommendations for initiating and maintaining treatment with an LAI
Practices/procedures

Recommendations

Agreeing to LAI trial

•
•
•
•

Choosing an agent

Consider:
• Patient’s previous response to specific antipsychotics, including history of side effects with different agents
• Metabolic and EPS side effects experienced with previous antipsychotics
• Out-of-pocket expense and formulary restrictions
• Clinician’s expectation of good tolerability and efficacy for specific LAI
• Availability of formulations with varying dosing intervals
• Option for deltoid or gluteal injection

LAI initiation

• Sufficient tolerability to the LAI should be established for the oral medication before initiating LAI with that
same molecule
• When starting LAI, use concomitant oral antipsychotic according to package insert
• Start with intended maintenance dose for most patients
• Give second injection according to schedule in package insert, unless symptoms increase before the end of
dosing interval

LAI trial

• Duration of trial should allow achievement of steady state or one to two cycles after steady state is reached
• Measure treatment response based on the presence of positive symptoms and/or functional status (SCZ) or
based on psychotic symptoms, manic/hypomanic symptoms, functional status, and/or mixed symptoms (BP)
• If steady state of maximum tolerated dose is reached but symptoms persist:
(SCZ) positive symptoms – switch to medication approved for treatment-resistant schizophrenia;
negative or cognitive symptoms – no first-line consensus
(BP) manic symptoms – add lithium or mood stabilizer or switch to a different mood stabilizer;
depressive or psychotic symptoms – no first-line consensus

Maintenance treatment

• Support continued injections through
Appointment reminders (by clinic [phone], family member, care partner, peer specialist, counselor)
LAI administration in the home by a mental health professional
• Address side effects
• Monitor body weight, BMI, blood pressure, liver function, metabolic parameters, prolactin, EPS

Discuss risks/benefits with patient and family/care partners
Obtain patient agreement
Document discussion with patient
Provide educational materials

Abbreviations: BMI, body mass index; BP, bipolar disorder; EPS, extrapyramidal symptoms; LAI, long-acting injectable antipsychotic; SCZ, schizophrenia/schizoaffective
disorder.

closely with those in the AFPBN guidelines for the use of
LAIs in serious mental illness18 while addressing additional
clinical topics and practical aspects of LAI treatment.
Before prescribing an LAI, the majority of experts in this
survey felt it was extremely important to discuss the risks/
benefits with the patient and family/care partners, obtain a
patient’s agreement to LAI treatment, and document discussion with a patient/care partner in the medical record when
initiating an LAI. Similarly, when partnering with patients,
they felt it was extremely important to explain the most
meaningful advantages of using an LAI,27 including a better
chance of preserving function and achieving long-term goals
if on continuous medication, a reduced risk of relapse, and
greater ease of adhering to treatment.
Experts in this survey determined that the most important patient-related factor in selecting a specific LAI
was a patient’s previous response to the respective oral
antipsychotic or LAI (if provided in the past). Although there
is limited guidance available in the published literature to
help choose a specific LAI for a particular patient, a review
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by Sacchetti et al28 suggests that LAIs appear to have similar
tolerability to oral antipsychotics, and the National Institute
for Health and Care Excellence (NICE) guidelines propose
using the same risk assessment criteria for selecting either
an LAI or an oral antipsychotic.29
Overall, expert consensus in this survey was achieved
for the appropriate treatment settings in which to initiate an
LAI. However, although experts agreed that efficacy and
tolerability of an oral antipsychotic should be established
before the initiation of a new LAI, there was little consensus
on the required duration of the oral treatment phase. AFPBN
guidelines recommend offering LAIs as first-line treatment
to patients, but if the patient is going to be switched from an
oral antipsychotic to an LAI, they recommend prescribing
the oral antipsychotic to establish an effective dose before
initiating the LAI.18 The NICE schizophrenia guidelines recommend starting with a small test dose of the LAI,29 whereas
the British Association of Psychopharmacology guidelines
for bipolar disorder recommend using an oral antipsychotic
to establish the best tolerated dose before initiating an LAI.30
Neuropsychiatric Disease and Treatment 2018:14
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Establishing ideal LAI treatment initiation strategies remains
an important knowledge gap that likely reflects a lack of both
prospective studies and data from observational databases
that might shed light on prescribing practices associated with
optimal outcomes.
Upon initiation of treatment with a specific LAI in an
individual with schizophrenia/schizoaffective or bipolar disorder, an appropriate injection schedule must be established.
The majority of the experts agreed that they would follow the
PI recommendations for the starting dose, use of a loading
dose, procedure for switching from an oral antipsychotic to
the LAI, and the interval between injections during the initiation of an LAI. The expert responses also showed that they
generally favor a relatively short interval (4–14 days) of oral
medication before initiating an LAI of the same molecule and
that they would not recommend continuing the oral medication for .6 weeks before starting the LAI. However, survey
responses showed no first-line ratings for the ideal time
interval between injections; high second-line ratings were
given for an interval ranging between 4 and 12 weeks, with
little support for shorter injection intervals. These recommendations complement the fact that most available LAIs have
an injection interval of $4 weeks.8 LAIs with longer dosing
intervals are an important consideration for patients who are
either unwilling or unable to make more frequent in-person
visits. Additional research needs to be conducted to determine
the effectiveness of the available LAIs with particular dosing
schedules and must include individual patient preferences/
characteristics. Such research should provide data to enable
a consensus on recommended dosing strategies.
Because the efficacy of an antipsychotic may vary
depending on the individual patient, determination of
treatment response is a high priority in the management of
LAIs. The majority of experts rated the presence of positive
symptoms such as psychosis, delusions, and hallucinations as
being an extremely important (ie, received the highest possible rating from a majority of the experts) factor in assessing
LAI response in an individual with schizophrenia/schizoaffective disorder. For bipolar disorder, the highest possible
rating (extremely important) was given by 79% of the experts
for assessing the occurrence of psychotic symptoms, manic/
hypomanic symptoms, functional status, and mixed symptoms. Depressive symptoms received the lowest ratings for
LAI response evaluation in individuals with bipolar disorder.
This may reflect the fact that more antipsychotic drugs have
US Food and Drug Administration approval for the treatment of bipolar mania compared with bipolar depression.31,32
Moreover, this seeming disconnect with the functional impact
of depression on outcomes may also stem from the fact that
Neuropsychiatric Disease and Treatment 2018:14
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LAIs have no indication for depression as monotherapy
and that other oral agents or psychosocial treatments will
need to be prescribed to address depression and/or negative
symptoms. The two LAIs currently approved for the treatment of bipolar I disorder, risperidone LAI and aripiprazole
once monthly, have shown efficacy in reducing or preventing
manic episodes, not depressive episodes.33–35
Long-term adherence to antipsychotics has historically
been an important issue for many individuals with schizophrenia/schizoaffective or bipolar disorder. It is important
to identify whether apparent lack of response is due to either
nonadherence or the illness itself. The majority of experts in
this survey believed that nonadherence and lack of efficacy
of non-clozapine oral antipsychotic drugs could not be properly identified without $1 trial of an LAI in schizophrenia/
schizoaffective or bipolar disorder; however, no first-line
consensus was achieved. Moreover, when respondents
were asked to define an adequate LAI trial in patients with
schizophrenia, no first-line consensus emerged. The experts
did give a high second-line rating for multiple cycles of LAI
injections being necessary to define an adequate LAI trial.
Similarly, no first-line consensus emerged in individuals
with bipolar disorder; however, the experts again gave high
second-line ratings to the number of injection cycles needed
to reach steady state or one to two injection cycles more than
needed to reach full steady state. An important consideration
in defining an adequate LAI trial is how the recommended
trial duration can be achieved in clinical practice. However,
an LAI trial is generally initiated after there has been an
indication of efficacy and tolerability of oral antipsychotic.
Therefore, the degree of stability or further improvement/
worsening after the switch to an LAI needs to be monitored in
an ongoing manner. Given the effort and monitoring burden
of clozapine therapy, using an LAI trial to clearly differentiate
pseudoresistance to an antipsychotic drug because of poor
adherence versus genuine lack of therapeutic response has
the potential to improve identification of individuals who
warrant a different treatment or clozapine trial. A broader
use of LAIs could help address the gross underutilization of
clozapine in many treatment settings.36,37
Another important consideration for the clinician who has
initiated LAI treatment is persistent residual symptoms or the
development of breakthrough symptoms in a patient who is
already at steady state for the maximum allowed or tolerated
dose. Experts achieved a first-line consensus for the strategy
of switching to a medication approved for treatment-resistant
schizophrenia in patients with continued positive symptoms
and failure on an LAI if this constituted at least a second
antipsychotic trial. However, no first-line recommendations
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emerged for the treatment of negative or cognitive symptoms,
likely owing to the fact that there are no approved and effective
treatments available for these two symptom constellations
that would provide the basis for a rational switch.38 With
regard to bipolar disorder, if a patient had ongoing manic
symptoms despite an LAI trial, first-line consensus emerged
for switching to a different mood stabilizer if the patient was
currently being treated with one, adding lithium, or adding an
anticonvulsant mood stabilizer if the patient had not previously
received one. These recommendations are consistent with
bipolar disorder guidelines.30,39 Unlike schizophrenia, where
there is no high-quality evidence for the efficacy of polypharmacy with a second antipsychotic40 and other psychotropic
agents,38 combination treatment with two mood stabilizers
or an antipsychotic with a mood stabilizer has demonstrated
efficacy and regulatory approval for bipolar disorder.30 No
first-line consensus was achieved for individuals with bipolar
disorder who had depressive or psychotic symptoms. However, additional reasons for a lack of first-line consensus for
treating residual negative/cognitive symptoms in individuals
with schizophrenia or depressive/psychotic symptoms in
individuals with bipolar disorder may relate to the limited
role of antipsychotic drugs with regard to these symptoms; a
hypothesis that is consistent with published findings.41,42
Notably, consistent with a recent expert guideline on the
definition of treatment-resistant schizophrenia,43 experts in
this survey also considered it prudent to have patients who
seem to not be responding to first-line treatments for schizophrenia/schizoaffective or bipolar disorder to undergo $1
trial with an LAI to rule out “pseudoresistance” due to insufficient treatment adherence.
The issue of how to switch a patient from one LAI to a different LAI is another important consideration for clinicians.
The lack of consensus in this survey, as well as the absence
of any associated first-line ratings for switching strategies,
reflects the lack of clinical research data available to guide
LAI switching. The AFPBN guidelines do provide limited
guidance concerning switching between LAIs. The AFPBN
first-line strategy is to initiate a new LAI only after discontinuing the current LAI while coordinating the switch such that
the time since the last injection will correspond to the interval
between both injections.18 In addition, it is recommended
that the initial dose of the new LAI should correspond to an
equivalent dose of the previous LAI if possible. Notably, the
expert recommendations from this survey acknowledge the
importance of considering pharmacokinetic properties when
switching between agents. More specifically, it is recommended that the appropriate time interval for initiating a new
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LAI should be based on how quickly the therapeutic levels
of both LAIs are attained, and the oral tolerability with the
new antipsychotic should be established before switching
agents. In addition, oral supplementation should be given
when switching to an LAI that takes a substantial amount of
time to reach therapeutic levels but not when switching to an
LAI that reaches therapeutic levels quickly.
With regard to adverse effect and physical health monitoring in individuals with schizophrenia, schizoaffective
disorder, or bipolar disorder treated with an LAI, expert
recommendations were generally consistent with those of
the International Society for Bipolar Disorders23 and the
European Psychiatric Association.22 Although there is limited
guidance from the published literature to help choose a
specific LAI for a particular patient, a review28 and a metaanalysis44 suggested that the tolerability of LAIs appears to be
similar to that of oral antipsychotics, and the NICE guidelines
propose using the same risk criteria to select either an LAI or
an oral antipsychotic.29 The AFBPN guidelines recommend
offering LAIs as first-line treatment, but in the event of a
switch from an oral antipsychotic to an LAI, they recommend
giving the oral antipsychotic for an appropriate length of time
to establish an effective dose before initiating the LAI.18 The
NICE schizophrenia guidelines recommend starting with a
small test dose of the LAI,29 whereas the British Association of Psychopharmacology guidelines for bipolar disorder
recommend using an oral antipsychotic to establish the best
tolerated dose before initiating an LAI.30
Limitations to the interpretation of this expert consensus
survey include low overall response rate and relatively small
sample size. Because the survey took about 2.5–3 hours to
complete, there is also a risk of inconsistent responses. Furthermore, although such an analysis would be of interest, an
insufficient number of responses were received to allow comparisons between responses from researchers and high-volume
clinical prescribers. It should also be noted that the survey
questions mostly considered LAIs as a group and did not
differentiate individual LAI-specific factors; however, some
of the differences were implicit when the survey respondents
were asked to consider the package inserts. Because the survey
was limited to US experts, the responses most likely reflected
opinion on atypical antipsychotics more so than typical
antipsychotics although the type of antipsychotic was not
specified in the survey. Expert recommendations were based
on consideration of clinical trial data, clinical experience, and
opinion. Although the latter could weaken the impact and
generalizability of the recommendations, expert consensus
can provide guidance in areas where clinicians need to make
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decisions and where clinical trial data are missing. Finally, the
recommendations reflect experiences of experts in the US; the
treatment landscape may differ in other countries. Strengths
of this study include a high overall survey completion rate,
the blinded format (survey respondents were not provided
information on funding source), and the national representation of experts. Importantly, the survey methodology has previously been used to provide guidance for treatment decisions
in individuals with schizophrenia45,46 and bipolar disorder.47

Conclusion
Although LAIs are widely available and have clinical benefits for individuals with schizophrenia/schizoaffective or
bipolar disorder, these agents are currently underutilized.
Because clinical data are lacking, the findings from this
expert consensus survey may help provide clinical guidance/
recommendations to clinicians on initiating and maintaining
LAIs in individuals with schizophrenia/schizoaffective or
bipolar disorder. These expert recommendations may also
provide a foundation for additional clinical research to better
understand the role of LAIs in these clinical groups.

Significant outcomes

• The most important factor in long-acting injectable antipsychotic (LAI) selection was patient response and/or the
side effect profile with previous antipsychotics.
• Experts agreed that oral antipsychotic efficacy and tolerability should be established before switching to an LAI, but
opinions varied with regard to the minimum time period.
• Because levels of adherence are frequently unclear, most
experts agreed that $1 adequate LAI trial is needed before
the lack of antipsychotic efficacy can be determined.
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Supplementary material
Table S1 Frequency of medical monitoring during and after the first 6 months of treatment with LAIs
During the first 6 months of LAI treatment
Experts’ endorsing option, n

Do not
monitor

Baseline

After
1 month

After
2 months

After
3 months

After
6 months

Body weight/BMI
Blood pressure
Electrocardiogram
Fasting glucose level
Fasting lipid levels
HbA1c
Liver function testing
Prolactin level if the patient is being treated with
a medication with the potential to raise prolactin
Standardized assessments for extrapyramidal
symptoms (parkinsonism, akathisia)
Standardized assessments for tardive dyskinesia
Waist circumference

0
2
16
0
0
2
5
10

30
29
17
28
28
27
24
15

28
20
6
9
7
3
5
4

24
13
1
4
3
0
1
2

24
20
1
16
12
11
12
10

29
23
8
23
23
23
15
16

5

22

17

11

22

22

5
15

25
16

7
7

6
8

17
14

25
16

Experts’ endorsing option, n

Do not
monitor

At 8 months

At 10 months

At 1 year

Every 6 months
thereafter

Every year
thereafter

Body weight/BMI
Blood pressure
Electrocardiogram
Fasting glucose level
Fasting lipid levels
HbA1c
Liver function testing
Prolactin level if the patient is being treated with
a medication with the potential to raise prolactin
Standardized assessments for extrapyramidal
symptoms (parkinsonism, akathisia)
Standardized assessments for tardive dyskinesia
Waist circumference

0
1
14
1
0
2
4
12

16
11
0
1
1
1
0
1

15
10
0
1
0
0
0
1

21
22
11
22
21
20
18
12

25
17
3
12
10
10
7
6

11
16
14
18
20
18
19
14

5

9

8

18

21

6

5
14

4
3

4
3

16
13

21
11

8
7

After the first 6 months of LAI treatment

Abbreviations: BMI, body mass index; LAI, long-acting injectable antipsychotic.
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